Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of the Tolerability, Safety, and Efficacy of Liposomal Curcumin in Combination With Radiation and Temozolomide in Patients With Newly Diagnosed High-Grade Gliomas

NCT05768919 is registered in ClinicalTrials.gov with SignPath Pharma, Inc. as lead sponsor.

NCT NCT05768919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05768919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of the Tolerability, Safety, and Efficacy of Liposomal Curcumin in Combination With Radiation and Temozolomide in Patients With Newly Diagnosed High-Grade Gliomas
Lead sponsor
SignPath Pharma, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 3, 2023
Completion date
May 31, 2027
Enrollment
30 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma